U.S. Immunosuppressant Drugs Market Size & Outlook
Related Markets
U.S. immunosuppressant drugs market highlights
- The U.S. immunosuppressant drugs market generated a revenue of USD 38,804.1 million in 2020 and is expected to reach USD 57,139.0 million by 2027.
- The U.S. market is expected to grow at a CAGR of 5.7% from 2021 to 2027.
- In terms of segment, monoclonal antibodies was the largest revenue generating drug class in 2020.
- Monoclonal Antibodies is the most lucrative drug class segment registering the fastest growth during the forecast period.
Immunosuppressant drugs market data book summary
| Market revenue in 2020 | USD 38,804.1 million |
| Market revenue in 2027 | USD 57,139.0 million |
| Growth rate | 5.7% (CAGR from 2020 to 2027) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Monoclonal Antibodies |
| Historical data | 2016 - 2019 |
| Base year | 2020 |
| Forecast period | 2021 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Calcineurin Inhibitors, MTOR Inhibitors, Antiproliferative Agents, Monoclonal Antibodies |
Other key industry trends
- In terms of revenue, U.S. accounted for 40.5% of the global immunosuppressant drugs market in 2020.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2027.
- In North America, U.S. immunosuppressant drugs market is projected to lead the regional market in terms of revenue in 2027.
- Canada is the fastest growing regional market in North America and is projected to reach USD 6,480.0 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Immunosuppressant Drugs Market Scope
Immunosuppressant Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| No records found. | ||||
U.S. immunosuppressant drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunosuppressant drugs market will help companies and investors design strategic landscapes.
Monoclonal antibodies was the largest segment with a revenue share of 76.17% in 2020. Horizon Databook has segmented the U.S. immunosuppressant drugs market based on calcineurin inhibitors, mtor inhibitors, antiproliferative agents, monoclonal antibodies covering the revenue growth of each sub-segment from 2016 to 2027.
The U.S. market is expected to witness lucrative growth due to key factors such as increasing awareness about oral hygiene and presence of sophisticated infrastructure pertaining to advanced dental treatment options.
According to the Adults Oral Health & Well Being Survey, 42 % of Americans don't see a dentist as often as they would like and only 15% of the surveyed population claims that the have an excellent oral health. As per the U.S. Center for Disease Control and Prevention (CDC), 84.9% of children from 2-17 years of age, 64.0% of adults from 18 to 64 years of age and 65.6% of adults aged 65 and above and visited a dentist in 2017.
Reasons to subscribe to U.S. immunosuppressant drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. immunosuppressant drugs market databook
-
Our clientele includes a mix of immunosuppressant drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. immunosuppressant drugs market, including forecasts for subscribers. This country databook contains high-level insights into U.S. immunosuppressant drugs market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. immunosuppressant drugs market size, by drug class, 2016-2027 (US$M)
U.S. Immunosuppressant Drugs Market Share, 2020 & 2027 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
